JP2019519529A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519529A5
JP2019519529A5 JP2018561669A JP2018561669A JP2019519529A5 JP 2019519529 A5 JP2019519529 A5 JP 2019519529A5 JP 2018561669 A JP2018561669 A JP 2018561669A JP 2018561669 A JP2018561669 A JP 2018561669A JP 2019519529 A5 JP2019519529 A5 JP 2019519529A5
Authority
JP
Japan
Prior art keywords
car
seq
nos
domain comprises
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018561669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519529A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/034691 external-priority patent/WO2017205747A1/en
Publication of JP2019519529A publication Critical patent/JP2019519529A/ja
Publication of JP2019519529A5 publication Critical patent/JP2019519529A5/ja
Priority to JP2022089863A priority Critical patent/JP2022130396A/ja
Priority to JP2024112931A priority patent/JP2024156707A/ja
Pending legal-status Critical Current

Links

JP2018561669A 2016-05-27 2017-05-26 Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法 Pending JP2019519529A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022089863A JP2022130396A (ja) 2016-05-27 2022-06-01 Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法
JP2024112931A JP2024156707A (ja) 2016-05-27 2024-07-12 Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662342394P 2016-05-27 2016-05-27
US62/342,394 2016-05-27
PCT/US2017/034691 WO2017205747A1 (en) 2016-05-27 2017-05-26 Flt3-specific chimeric antigen receptors and methods using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022089863A Division JP2022130396A (ja) 2016-05-27 2022-06-01 Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法

Publications (2)

Publication Number Publication Date
JP2019519529A JP2019519529A (ja) 2019-07-11
JP2019519529A5 true JP2019519529A5 (enExample) 2020-07-09

Family

ID=59054226

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018561669A Pending JP2019519529A (ja) 2016-05-27 2017-05-26 Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法
JP2022089863A Pending JP2022130396A (ja) 2016-05-27 2022-06-01 Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法
JP2024112931A Pending JP2024156707A (ja) 2016-05-27 2024-07-12 Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022089863A Pending JP2022130396A (ja) 2016-05-27 2022-06-01 Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法
JP2024112931A Pending JP2024156707A (ja) 2016-05-27 2024-07-12 Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法

Country Status (6)

Country Link
US (2) US11299546B2 (enExample)
EP (2) EP4413999A3 (enExample)
JP (3) JP2019519529A (enExample)
AU (1) AU2017271606B2 (enExample)
CA (1) CA3025516A1 (enExample)
WO (1) WO2017205747A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11299546B2 (en) * 2016-05-27 2022-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services FLT3-specific chimeric antigen receptors and methods using same
JP7286658B2 (ja) 2017-09-26 2023-06-05 セロ・セラピューティクス・インコーポレイテッド キメラエンガルフメント受容体分子および使用方法
EP3774906A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
AU2019243154A1 (en) 2018-03-28 2020-10-01 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
AU2019404098A1 (en) 2018-12-18 2021-05-27 Boehringer Ingelheim Io Canada Inc. FLT3 agonist antibodies and uses thereof
JP2022526194A (ja) * 2019-04-10 2022-05-23 エレベートバイオ テクノロジーズ，インコーポレイテッド Ｆｌｔ３特異的キメラ抗原受容体およびその使用方法
CA3133333A1 (en) 2019-04-30 2020-04-30 Brian Scott GARRISON Chimeric receptors and methods of use thereof
US20210253696A1 (en) * 2020-01-21 2021-08-19 Cero Therapeutics, Inc. Bivalent chimeric engulfment receptors and uses thereof
US20230174614A1 (en) * 2020-04-30 2023-06-08 Terry J FRY Multispecific anti-flt3 chimeric antigen receptors
CN116410315A (zh) * 2021-12-31 2023-07-11 博生吉医药科技(苏州)有限公司 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EA201990959A1 (ru) 2012-04-11 2020-02-10 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
WO2014164544A1 (en) * 2013-03-09 2014-10-09 Baylor College Of Medicine Vascular-targeted t-cell therapy
SG11201604565WA (en) 2013-12-06 2016-07-28 Us Health Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
JP2017513818A (ja) * 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
SG10201913765YA (en) * 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
AU2015344769B2 (en) * 2014-11-12 2020-07-09 Allogene Therapeutics, Inc. Inhibitory chimeric antigen receptors
KR20180053744A (ko) 2015-09-23 2018-05-23 사이토이뮨 테라퓨틱스 엘엘씨 면역 요법을 위한 flt3 유도된 car 세포
JP7208010B2 (ja) * 2016-03-29 2023-01-18 ユニバーシティ オブ サザン カリフォルニア 癌を標的とするキメラ抗原受容体
CA3018253A1 (en) * 2016-03-31 2017-10-05 University Of Southern California A highly sensitive and specific luciferase based reporter assay for antigen detection
US11299546B2 (en) * 2016-05-27 2022-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services FLT3-specific chimeric antigen receptors and methods using same
US20230174614A1 (en) * 2020-04-30 2023-06-08 Terry J FRY Multispecific anti-flt3 chimeric antigen receptors

Similar Documents

Publication Publication Date Title
JP2019519529A5 (enExample)
JP2018531014A5 (enExample)
FI3946621T3 (fi) Mage a4 -t-solureptoreja
JP2016502512A5 (enExample)
JP2018029594A5 (enExample)
EP4282878A3 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
JP2017537622A5 (enExample)
RU2015117237A (ru) Химерные антигенные рецепторы м971
JP2016538830A5 (enExample)
JP2019506841A5 (enExample)
JP2020517635A5 (enExample)
JP2017513478A5 (enExample)
JP2014534207A5 (enExample)
JP2018505139A5 (enExample)
JP2016520074A5 (enExample)
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
JP2018504145A5 (enExample)
JP2017526361A5 (enExample)
JP2016532693A5 (enExample)
JP2017528158A5 (enExample)
JP2019527557A5 (enExample)
JP2018529327A5 (enExample)
JP2018064568A5 (enExample)
JP2016527286A5 (enExample)
JP2018523484A5 (enExample)